Quynh-ThuXuanLeMDFASTRO

Radiation Oncology • Stanford, CA

Head & Neck

Professor, Radiation Oncology, Stanford University Medical Center

Join to view full profile

Dr. Le is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Le's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Fax+1 650-725-8231

Summary

Dr. Quynh-Thu Le is a radiation oncologist in Stanford, CA and is affiliated with multiple hospitals in the area, including Lucile Packard Children's Hospital Stanford, Stanford Health Care, and VA Palo Alto Health Care System. She received her medical degree from University of California San Francisco School of Medicine and has been in practice 24 years. She specializes in head & neck.

Education & Training

University of California (San Francisco)Residency, Radiation Oncology, 1994 - 1997
Alameda Health System-Highland HospitalInternship, Transitional Year, 1993 - 1994
University of California San Francisco School of MedicineClass of 1993

Certifications & Licensure

CA State Medical License 1994 - 2026
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer Start of enrollment: 2000 Oct 01
Completed
Phase 1
Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer Start of enrollment: 2003 Sep 01
Completed
Phase 2
Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck Start of enrollment: 2002 Jun 01
Completed
Phase 1
Identification of Serum Markers For Tumor Hypoxia in Non-Small Cell Lung Cancers Start of enrollment: 2000 Sep 01
Completed
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations Start of enrollment: 2001 Nov 01
Completed
Treatment Outcomes and Quality of Life After IMRT Treatments of Head and Neck Cancers Start of enrollment: 2003 Apr 01
Completed
The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers Start of enrollment: 2003 May 01
Completed
Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast Start of enrollment: 2003 Feb 01
Completed
Not Applicable
Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer Start of enrollment: 2002 Apr 02
Recruiting
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy Start of enrollment: 2002 Jan 01
Recruiting
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy Start of enrollment: 2007 Jul 01
Terminated
Phase 2
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers Start of enrollment: 1998 Sep 01
Recruiting
Real-Time kV Imaging vs. Real-Time 3D Patient Surface Tracking for Head & Neck Cancer Start of enrollment: 2009 Oct 01
Terminated
Not Applicable
Imaging and Biomarkers of Hypoxia in Solid Tumors Start of enrollment: 2010 Dec 01
Terminated
Phase 1
Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers Start of enrollment: 2010 Aug 01
Completed
Phase 1
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer Start of enrollment: 2013 Mar 22
Recruiting
Phase 2, Phase 3
Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery Start of enrollment: 2016 Feb 01
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer.
Li Guan, Pedro A Torres-Saavedra, Xiaobei Zhao, Michael B Major, Brittany J Holmes
Clinical Cancer Research. 2024-12-10
1 citations
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label,...
Loren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, Julie A Kish, Steven S Chang
The Lancet. Oncology. 2024-12-01
International Recommendations on Postoperative Management for Potentially Resectable Locally Recurrent Nasopharyngeal Carcinoma.
Ji-Shi Li, Pierre Blanchard, Charlene H L Wong, Yong Chan Ahn, Pierluigi Bonomo
International Journal of Radiation Oncology, Biology, Physics. 2024-12-01

Journal Articles

International Guideline for the Delineation of the Clinical Target Volumes (CTV) for Nasopharyngeal Carcinoma
William M. Mendenhall, Qunyh-Thu Le, Nancy Y. Lee, Radiotherapy & Oncology

Press Mentions

RSNA 2022 Plenaries Highlight Radiology’s Value, Responsibility to PatientsJuly 19th, 2022
Traditional Chemotherapy Superior to New Alternative for Oropharyngeal CancersNovember 15th, 2018
NRG Oncology Selects Health Equity Fellows for 2024February 22nd, 2024

Grant Support

Targeting Galectin-1 With Radiation In Lung CancerNational Cancer Institute2012
A Novel Therapy For Radiation-Induced Xerostomia Using Human Salivary Stem CellsNational Institute Of Dental &Craniofacial Research2011
Osteopontin &Tumor Progression In Head And Neck CancersNational Cancer Institute2007–2011
Defining Molecular Markers For Tumor HypoxiaNational Cancer Institute2006–2010
Markers For Tumor Hypoxia In Head And Neck CancerNational Cancer Institute2001–2002